149 related articles for article (PubMed ID: 35427563)
41. Antileishmanial activity of a 4-hydrazinoquinoline derivative: Induction of autophagy and apoptosis-related processes and effectiveness in experimental cutaneous leishmaniasis.
Antinarelli LMR; de Oliveira Souza I; Zabala Capriles PV; Gameiro J; Britta EA; Nakamura CV; Lima WP; da Silva AD; Coimbra ES
Exp Parasitol; 2018 Dec; 195():78-86. PubMed ID: 30385267
[TBL] [Abstract][Full Text] [Related]
42. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.
Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R
Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770
[TBL] [Abstract][Full Text] [Related]
43. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.
Fournet A; Ferreira ME; Rojas De Arias A; Torres De Ortiz S; Fuentes S; Nakayama H; Schinini A; Hocquemiller R
Antimicrob Agents Chemother; 1996 Nov; 40(11):2447-51. PubMed ID: 8913444
[TBL] [Abstract][Full Text] [Related]
44. Amentoflavone as an Ally in the Treatment of Cutaneous Leishmaniasis: Analysis of Its Antioxidant/Prooxidant Mechanisms.
Rizk YS; Santos-Pereira S; Gervazoni L; Hardoim DJ; Cardoso FO; de Souza CDSF; Pelajo-Machado M; Carollo CA; de Arruda CCP; Almeida-Amaral EE; Zaverucha-do-Valle T; Calabrese KDS
Front Cell Infect Microbiol; 2021; 11():615814. PubMed ID: 33718267
[TBL] [Abstract][Full Text] [Related]
45. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis.
Kückelhaus CS; Kückelhaus SA; Muniz-Junqueira MI
Exp Parasitol; 2011 Mar; 127(3):658-64. PubMed ID: 21176775
[TBL] [Abstract][Full Text] [Related]
46. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.
Pratti JE; Ramos TD; Pereira JC; da Fonseca-Martins AM; Maciel-Oliveira D; Oliveira-Silva G; de Mello MF; Chaves SP; Gomes DC; Diaz BL; Rossi-Bergmann B; de Matos Guedes HL
Parasit Vectors; 2016 Oct; 9(1):534. PubMed ID: 27716449
[TBL] [Abstract][Full Text] [Related]
48. N-acetyl-L: -cysteine reduces the parasitism of BALB/c mice infected with Leishmania amazonensis.
Monteiro MC; Marques FC; Blazius RD; Santos da Silva O; de Queiroz Cunha F; Bento DB; Torres Romão PR
Parasitol Res; 2008 Mar; 102(4):801-3. PubMed ID: 18094999
[TBL] [Abstract][Full Text] [Related]
49. 2'-Hydroxyflavanone activity in vitro and in vivo against wild-type and antimony-resistant Leishmania amazonensis.
Gervazoni LFO; Gonçalves-Ozório G; Almeida-Amaral EE
PLoS Negl Trop Dis; 2018 Dec; 12(12):e0006930. PubMed ID: 30521527
[TBL] [Abstract][Full Text] [Related]
50. Epoxy-α-lapachone has in vitro and in vivo anti-leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite.
Souza-Silva F; Bourguignon SC; Pereira BA; Côrtes LM; de Oliveira LF; Henriques-Pons A; Finkelstein LC; Ferreira VF; Carneiro PF; de Pinho RT; Caffarena ER; Alves CR
Antimicrob Agents Chemother; 2015 Apr; 59(4):1910-8. PubMed ID: 25583728
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
52. Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.
Varikuti S; Oghumu S; Saljoughian N; Pioso MS; Sedmak BE; Khamesipour A; Satoskar AR
Acta Trop; 2017 Sep; 173():102-108. PubMed ID: 28602835
[TBL] [Abstract][Full Text] [Related]
53. Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis.
Guimarães ET; Lima MS; Santos LA; Ribeiro IM; Tomassini TB; Ribeiro dos Santos R; dos Santos WL; Soares MB
J Antimicrob Chemother; 2009 Jul; 64(1):84-7. PubMed ID: 19454526
[TBL] [Abstract][Full Text] [Related]
54. Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
Lanza JS; Fernandes FR; Corrêa-Júnior JD; Vilela JM; Magalhães-Paniago R; Ferreira LA; Andrade MS; Demicheli C; Melo MN; Frézard F
Int J Nanomedicine; 2016; 11():2305-18. PubMed ID: 27307731
[TBL] [Abstract][Full Text] [Related]
55. Study of the efficacy of N-methyl glucamine antimoniate (Sb
Ribeiro JBP; Miranda-Vilela AL; Amorim AAS; Garcia RD; Moreira JR; Gomes CM; Takano GHS; de Oliveira GMF; Lima AV; da Silva ICR; Sampaio RNR
Photodiagnosis Photodyn Ther; 2019 Jun; 26():261-269. PubMed ID: 30951865
[TBL] [Abstract][Full Text] [Related]
56. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
57. In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
García Bustos MF; Barrio A; Prieto GG; de Raspi EM; Cimino RO; Cardozo RM; Parada LA; Yeo M; Soto J; Uncos DA; Parodi C; Basombrío MA
J Parasitol; 2014 Dec; 100(6):840-7. PubMed ID: 25014108
[TBL] [Abstract][Full Text] [Related]
58. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
Nakayama H; Loiseau PM; Bories C; Torres de Ortiz S; Schinini A; Serna E; Rojas de Arias A; Fakhfakh MA; Franck X; Figadère B; Hocquemiller R; Fournet A
Antimicrob Agents Chemother; 2005 Dec; 49(12):4950-6. PubMed ID: 16304157
[TBL] [Abstract][Full Text] [Related]
60. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
